Search

Your search keyword '"Laszlo, D"' showing total 239 results
Start Over Author "Laszlo, D" Language english
239 results on '"Laszlo, D"'

3. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

Author

Necchi, A, Miceli, R, Bregni, M, Bokemeyer, C, Berger, L A, Oechsle, K, Schumacher, K, Kanfer, E, Bourhis, J H, Massard, C, Laszlo, D, Montoro, J, Flechon, A, Arpaci, F, Secondino, S, Wuchter, P, Dreger, P, Crysandt, M, Worel, N, Kruger, W, Ringhoffer, M, Unal, A, Nagler, A, Campos, A, Wahlin, A, Michieli, M, Sucak, G, Donnini, I, Schots, R, Ifrah, N, Badoglio, M, Martino, M, Raggi, D, Giannatempo, P, Rosti, G, Pedrazzoli, P, and Lanza, F

Published
2016
Full Text
View/download PDF

6. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2′-deoxyadenosine (2-CdA) and Rituximab

Author

Rabascio, C., Laszlo, D., Andreola, G., Saronni, L., Radice, D., Rigacci, L., Fabbri, A., Frigeri, F., Calabrese, L., Billio, A., Bertolini, F., and Martinelli, G.

Published
2010
Full Text
View/download PDF

32. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma

Author

Lanza, F., Lemoli, R. M., Olivieri, A., Laszlo, D., Martino, M., Specchia, G., Pavone, V., Imola, M., Pasini, A., Milone, G., Scortechini, I., Todisco, E., Guggiari, E., Cascavilla, N., Martinelli, G., Rambaldi, A., and Bosi, A.

Subjects
Adult, Male, Benzylamines, Receptors, CXCR4, Adolescent, Lymphoma, Cyclams, NO, Aged, Blood Component Removal, Chemoradiotherapy, Data Collection, Female, Hematopoietic Stem Cell Mobilization, Heterocyclic Compounds, Humans, Italy, Leukapheresis, Middle Aged, Multiple Myeloma, Platelet Count, Predictive Value of Tests, Prospective Studies, Young Adult, Receptors, CXCR4
Abstract

Although the efficacy of plerixafor in peripheral blood stem cell (PBSC) mobilization has been explored in several studies, factors associated with successful plerixafor mobilization after administration of granulocyte-colony-stimulating factor (G-CSF), with or without chemotherapy, have not been investigated. We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients.Two endpoints were established to define successful mobilization: patients with at least 2 × 10(6) CD34+ cells/kg collected by three leukapheresis procedures and patients achieving a peak count of at least 20 × 10(6) CD34+ cells/L during mobilization.Plerixafor achieved successful mobilization in both predicted (n = 64) and proven poor mobilizers (PMs; n = 143), classified according to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) criteria. Successful mobilization was independent of type of mobilization (steady state or chemotherapy); age; sex; disease; number or type of chemotherapy regimens preceding plerixafor; radiation therapy; prior treatment with melphalan, carmustine, lenalidomide, and radioimmune conjugates; and laboratory variables. Multivariate analysis identified previous fludarabine treatment and premobilization platelet count as predictors of successful mobilization.This large, prospective, nationwide study confirmed plerixafor efficacy for mobilizing PBSCs when added to G-CSF with or without chemotherapy. Plerixafor can overcome negative effects of most predictors of poor mobilization to achieve satisfactory harvest both in predicted and proven PM.

Published
2014

33. Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis

Author

Gardellini, A, Gigli, F, Babic, A, Andreola, G, Radice, D, Sammassimo, S, Martinelli, G, and Laszlo, D

Subjects
biosimilar G-CSF, lenograstim, Research, autologous bone marrow transplantation, filgrastim, engraftment
Abstract

Purpose Granulocyte colony-stimulating factors (G-CSFs), filgrastim and lenograstim, are recognised to be useful in accelerating engraftment after autologous stem cell transplantation. Several forms of biosimilar non-glycosylated G-CSF have been approved by the European Medicines Agency, with limited published data supporting the clinical equivalence in peripheral blood stem cell mobilisation and recovery after autologous stem cell transplantation. Method With the aim of comparing cost-effective strategies in the use of G-CSF after autologous stem cell transplantation, we retrospectively evaluated 32 patients consecutively treated with biosimilar filgrastim XM02 (Tevagrastim) and 26 with lenograstim. All patients received G-CSF (biosimilar or lenograstim) at a dosage of 5 mcg/kg/day subcutaneously from day 5 to absolute neutrophil count of 1500/mmc for three days. Results The median time to absolute neutrophil count engraftment was 11 days for the filgrastim XM02 group and 12 days for the lenograstim group. As for platelets recovery, the median time was 12 days in both groups. The median number of G-CSF vials used for patients was 9.5 for Tevagrastim and 10.5 for lenograstim, reflecting a mean estimated cost of about 556.1 euros for Tevagrastim versus 932.2 euros for lenograstim (p< 0.001). The median days of febrile neutropenia were 1.5 and 1 for filgrastim XM02 and lenograstim, respectively. No adverse event related to the use of XM02 filgrastim was recorded. Conclusion In our experience, filgrastim XM02 and lenograstim showed comparable efficacy in shortening the period of neutropenia after cytoreduction and autologous stem cell transplantation, with a favourable cost effect for filgrastim XM02.

Published
2013

41. 860P - Impact of Response to Induction Chemotherapy in Patients with Germ Cell Tumors (Gct) Receiving Salvage High-Dose Chemotherapy (Hdct): a Study of the Ebmt Solid Tumors Working Party (Stwp)

Author

Necchi, A., Miceli, R., Berger, L.A., Schumacher, K., Bourhis, J.H., Laszlo, D., Nicolas-Virelizier, E., Arpaci, F., Secondino, S., Dreger, P., Kruger, W., Ringhoffer, M., Unal, A., Nagler, A., Campos, A., Wahlin, A., Donnini, I., Badoglio, M., Pedrazzoli, P., and Lanza, F.

Published
2014
Full Text
View/download PDF

45. Idarubicin Containing Regimen in Multiply Myeloma: Preliminary Results of a Pilot Study Using a Modified 'TANDEM' Transplant Program.

Author

Martinelli, G., Agazzi, A., Laszlo, D., Santoro, P., Mancuso, P., Pruneri, G.C., Greco, P., and Bertolini, F.

Subjects
MULTIPLE myeloma treatment, AUTOTRANSPLANTATION
Abstract

Tandem autologous transplant actually represents a challenge in multiple myeloma treatment, but the best conditioning regimen is still under investigation. With the aim of evaluating the feasibility of a modified tandem transplant strategy, we treated 10 multiple myeloma patients after conventional first line chemotherapy with a two step conditioning regimen consisting of high-dose melphalan (200 mg/m²) followed by high-dose melphalan (180 mg/m²) together with indarubicin (15 mg/sqm² c.i. × 3 days) both with peripheral stem cell support. At first transplant, the median age was 62 years, performance status was good and disease status was CR in 2 patients and PR in the rest. At the end of the first transplant, 70% of patients achieved CR and only mild toxicity was observed. After the second transplant further improvement of the response rate was obtained with 90% CR. However, we observed three toxic early infection-related deaths from CMV and legionella pneumonia at day +17, +26, +54 after transplantation. Although this schedule seems to be effective in terms of response rate, the 30% TRM imposes an anthracycline dose-reduction with careful patient selection. This approach could reduce the toxic effects and maintain the efficacy of therapy at the same time. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

47. ANAPLASTIC LARGE CELL LYMPHOMA, ALK‐NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T‐CELL PROJECT.

Author

Shustov, A., Cabrera, M., Bellei, M., Civallero, M., Ko, Y.H., Manni, M., Horwitz, S.M., Antonio De Souza, C., Radford, J., Varela, S.B., Prates, M.V., Ferreri, A., Chiattone, C., Spina, M., Vose, J.M., Chiappella, A., Laszlo, D., Marino, D., Stelitano, C., and Skrypets, T.

Subjects
LYMPHOMAS, CASE studies, ANAPLASTIC large-cell lymphoma, THERAPEUTICS, CELLS
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results